Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Oncology
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland
Andrea Favre-Bullea MSD, Lucerne, SwitzerlandCorrespondence[email protected]
https://orcid.org/0000-0001-7276-9706
https://orcid.org/0000-0001-7276-9706, Goran Bencinab MSD, Madrid, Spainhttps://orcid.org/0000-0001-6293-8211
https://orcid.org/0000-0001-6293-8211, Shujing Zhangc Merck & Co., Inc, Rahway, NJ, USAhttps://orcid.org/0000-0001-8956-1725
https://orcid.org/0000-0001-8956-1725, Ruixuan Jiangc Merck & Co., Inc, Rahway, NJ, USAhttps://orcid.org/0000-0003-1737-2989
https://orcid.org/0000-0003-1737-2989, Daniel Andritschkea MSD, Lucerne, Switzerlandhttps://orcid.org/0000-0002-8918-7777
https://orcid.org/0000-0002-8918-7777 & Arjun Bhadhurid Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerlandhttps://orcid.org/0000-0003-1220-0731
https://orcid.org/0000-0003-1220-0731